Vancomycin-resistant enterococcus in pediatric oncology patients: An analysis of potential consequences of colonization and infection.
A retrospective analysis of 57 pediatric oncology patients with a baseline positive vancomycin-resistant enterococcus (VRE) culture who subsequently received chemotherapy and/or radiation therapy was performed. The incidence of subsequent VRE infection was calculated using a competing risk analysis accounting for death from non-VRE causes as a competing risk. Ten patients had subsequent VRE infection. The cumulative incidence of subsequent infection was 14% (7-27%, 95% confidence interval) at 1 year and 16% (9-29%, 95% confidence interval) at 2 years. None of the hypothesized risk factors appeared to differ between patients who developed a subsequent infection and those who did not.
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Amanda
A
Kosack
Elyn
E
Riedel
Timothy E
TE
Kiehn
Trudy N
TN
Small
Leonard H
LH
Wexler
Ira J
IJ
Dunkel
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D016983:Enterococcus; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000150:complications*; D012189:Retrospective Studies; D013290:Streptococcal Infections / Q000209:etiology*; D020713:Vancomycin Resistance; D055815:Young Adult